Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antigen-based immune modulation: DNA vectors and beyond.

Adrian Bot1, William J Phillips, Matthias von Herrath

  • 1AlleCure Corporation, 28903 North Avenue Paine, Valencia, CA 91355, USA. abot@allecure.com

Expert Opinion on Biological Therapy
|January 9, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Response to the Letter to the Editor: Supporting a Neuroprotective Effect of Lorlatinib Across ALK and ROS1 Targets.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

CAR-T cells targeting fibroblast activation protein eliminate pathological fibroblasts and preserve cardiac function in a Duchenne Muscular Dystrophy murine model.

Stem cell research & therapy·2026
Same author

Targeted Lipid Nanoparticle Delivery of FAP-CAR mRNA Enables Potent In Vivo T-cell Engineering against Pancreatic Tumors.

Cancer immunology research·2026
Same author

The dawn of in vivo immune cell engineering in oncology.

Nature biotechnology·2026
Same author

Hiding in Plain Sight: The Neuro-Protective Benefit of Tropomyosin Receptor Kinase Inhibition in Non-Neurotrophic Receptor Tyrosine Kinase-Driven Lung Cancers.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

Phase I Clinical Trial of Islet Antigen-Specific Plasmid Coexpressing Tolerogenic Proteins Demonstrates Safety in Adults With Type 1 Diabetes.

Diabetes·2026
Same journal

TNF inhibitors for the long-term management of juvenile idiopathic arthritis associated uveitis: real-life data from the ITHACA cohort.

Expert opinion on biological therapy·2026
Same journal

Type 2 inflammation and biologics: a twenty-year journey.

Expert opinion on biological therapy·2026
Same journal

Current outlook on the use of biological agents to improve outcomes in adult secondary hemophagocytic lymphohistiocytosis.

Expert opinion on biological therapy·2026
Same journal

Addressing challenges in disease management of childhood-onset systemic lupus erythematosus: the role of biologics, with primary focus on rituximab and belimumab.

Expert opinion on biological therapy·2026
Same journal

Biological drugs for the treatment of children with atopic dermatitis.

Expert opinion on biological therapy·2026
Same journal

Optimizing biologic therapy in psoriasis: dose adjustment, treatment duration, and tapering-an expert perspective.

Expert opinion on biological therapy·2026
See all related articles

Developing novel plasmid vectors for autoimmune immunotherapy aims to specifically target harmful immune responses. Researchers are exploring ways to enhance efficacy and safety for next-generation treatments.

Area of Science:

  • Immunology
  • Immunotherapy
  • Autoimmune Diseases

Background:

  • The goal of autoimmune immunotherapy is to specifically reduce autoaggressive immune responses while preserving normal immune functions.
  • Antigen-based immune modulation showed promise but faced clinical translation challenges due to inherent limitations.
  • Novel antigen delivery vectors are being investigated to improve the efficiency of antigen-dependent immune modulation.

Purpose of the Study:

  • To explore the potential of plasmid vectors for antigen delivery in autoimmune immunotherapy.
  • To address the challenges and safety concerns associated with using plasmid vectors.
  • To provide a perspective on current efforts and future directions for plasmid-based immunotherapeutics.

Main Methods:

  • Investigation of plasmid vectors as a delivery system for antigens.

Related Experiment Videos

  • Analysis of the prolonged, limited antigen production by plasmid vectors.
  • Exploration of strategies to mitigate the "danger" signal from unmethylated CpG motifs in plasmids.

    • Main Results:

    • Plasmid vectors offer prolonged, limited antigen production, potentially enhancing immune modulation.
    • Unmethylated CpG motifs in plasmids can act as an inherent "danger" signal, complicating their use.
    • Various approaches are being developed to improve plasmid efficacy and safety for immunotherapy.

    Conclusions:

    • Plasmid vectors represent a promising tool for advancing autoimmune immunotherapy.
    • Overcoming safety concerns related to CpG motifs is crucial for successful clinical translation.
    • Continued research into novel vectors and strategies will lead to next-generation immunotherapeutics.